Skip to main content

Peptide and GLP-1 dosage

Peptide dosage charts and schedules

Choose a compound to see where its dose comes from. Of the 36 compounds covered, 2 have one approved schedule and 1 have schedules that change by product. Another 6 have doses tested in human trials. The remaining 27 have no approved or trial-based schedule.

Source: Based on 36 compound guides and 8 FDA brand labels

What matters first

Molecule-wide label schedules
2
Product-specific label sets
1
Published trial arms
6
No label or trial schedule
27

Which compounds have a dose schedule at all?

One row per record. The middle column is the whole point: it says what the numbers rest on, and a dash means nobody has published any.

◆ 2 molecule label · 1 product-label set · 6 trial-only · 8 reported-only · 19 with nothing36 records
Every compound guide, with what its dose numbers rest on, how many steps or arms it includes, the range those cover, and how strong the evidence is
CompoundNumbers come fromSteps, arms or productsRange coveredGrade
SemaglutideApproved label50.25–2.4 mgFDA label
TirzepatideApproved label62.5–15 mgFDA label
LiraglutideProduct labels2Victoza ≤1.8 mg · Saxenda ≤3 mgFDA label
CagrilintideTrial arms50.3–4.5 mgHuman trial
MazdutideTrial arms24–6 mgHuman trial
PemvidutideTrial arms31.2–2.4 mgHuman trial
RetatrutideTrial arms41–12 mgHuman trial
SurvodutideTrial arms40.6–4.8 mgHuman trial
VK2735Trial arms42.5–15 mgHuman trial
AHK-CuNothing published——no human dose shown to work
AOD-9604Nothing published——limited human data
BPC-157Nothing published——no human dose shown to work
CJC-1295Nothing published——limited human data
DSIPNothing published——limited human data
EpitalonNothing published——limited human data
GHK-CuNothing published——indirect evidence
HexarelinNothing published——limited human data
IGF-1 LR3Nothing published——no human dose shown to work
IpamorelinNothing published——Human trial
Kisspeptin-10Nothing published——limited human data
KPVNothing published——no human dose shown to work
LL-37Nothing published——limited human data
Melanotan IINothing published——limited human data
MOTS-cNothing published——no human dose shown to work
NAD+Nothing published——limited human data
PEG-MGFNothing published——no human dose shown to work
PinealonNothing published——limited human data
PT-141Nothing published——FDA label
SelankNothing published——limited human data
SemaxNothing published——limited human data
SermorelinNothing published——limited human data
SS-31Nothing published——FDA label
TB-500Nothing published——indirect evidence
TesamorelinNothing published——FDA label
Thymosin alpha-1Nothing published——limited human data
ZenagamtideNothing published——Human trial

Steps are titration rows on a label. Arms are dose groups in a trial. A product count means the molecule has multiple labeled schedules that remain separate on its page. They share a column because all three are the source objects a page has to work from—not because they mean the same thing.

Does a brand stop where its own drug’s chart stops?

Not always. 3 of these 8 products stop somewhere other than the molecule chart they sit on top of. A ceiling belongs to a label, and each label sets its own.

For each brand: its starting dose, its top dose, and the top dose on the molecule chart it is built on
BrandDrug insideStarts atStops atMolecule chart stops at
WegovySemaglutide0.25 mg7.2 mg2.4 mg
OzempicSemaglutide0.25 mg2 mg2.4 mg
ZepboundTirzepatide2.5 mg15 mg15 mg
MounjaroTirzepatide2.5 mg15 mg15 mg
TrulicityDulaglutide0.75 mg4.5 mg—
VictozaLiraglutide0.6 mg1.8 mg—
SaxendaLiraglutide0.6 mg3 mg—
RybelsusSemaglutide3 mg14 mg2.4 mg

The last column is the top step on the molecule’s own chart, which is read from one label. A highlighted figure marks a product whose ceiling differs from it.

Two of these brands carry semaglutide and two carry tirzepatide. The rest of what separates the four labels — who they cover, what they treat, how a missed week is handled — sits with the brand pages.

One semaglutide schedule is missing from that table, and it is missing because it does not fit the columns. The tablet ladders run in 30-day blocks rather than weeks, across three products whose strengths do not convert into each other.

A second molecule now comes as a tablet too, and its schedule is a different shape again: six strengths climbing to a maximum the label never calls a settled dose. The orforglipron chart carries it, with the 9 mg cap that other medicines put on the top of it.

What is a dosage chart, really?

It is the end of a regulatory process. A sponsor runs trials, an agency reviews them, and the schedule that survives is printed on a label the manufacturer is then bound to.

That is why a chart cannot be written for a compound that has not been through it. There is no document to quote from. Sites that publish one anyway have built it backwards: they take a dose from a trial and invent a ramp that arrives there. The result looks exactly like a sourced schedule.

Trial arms are a different object again. An arm exists to map a range, so the lowest one is usually placed where the effect is expected to be small and the highest one where it starts to be hard to tolerate. Neither is a target. Reading the top arm as a goal is the most common mistake made with the 6 records in the middle group above.

The 27 records at the bottom have no label or trial schedule, and their pages say so. For 8 of them that is not the end of it: a range is circulating, so the range is shown it with the source that documents it and what the evidence does not show. The remaining 19 stop at the absence, because nothing is published to report.

How does a dose in milligrams become units on a syringe?

By division, twice. The chart gives a mass in milligrams. The syringe is marked in units, and what a unit holds depends on how the vial was mixed.

Worked once: 10 mg mixed with 2 mL of water is 5.00 mg/mL. A 2.5 mg dose is then 0.50 mL, which on a U-100 barrel reads as 50 units. Change the water and every unit figure changes while the dose does not.

Branded pens skip all of this, because the dose is set in the device. The calculator does the same arithmetic for any vial, and prints each step so it can be checked by hand.

Questions about dose schedules

Why do some compounds here have a chart and others do not?

Because a chart is a claim about where numbers came from. Where an approved label sets out a schedule, this site quotes it row by row and cites the label under the table. Where none exists, there is nothing to quote.

Is a trial dose a dose anyone can follow?

No. A trial gives stated amounts to selected people under monitoring, and it reports what happened. It does not establish a schedule, and no regulator has reviewed one. The pages for those 6 compounds report the arms and say so.

Why is the same drug listed at two different top doses?

Because the ceiling belongs to a product, not to a drug. Two brands built on the same drug are approved for different things, so their labels stop in different places. The table above marks every product where that happens.

Does mixing a vial differently change the dose?

No. Adding more water spreads the same powder through more liquid. The dose in milligrams is unchanged; the number of units you draw goes up. That is why every unit figure on this site names the mix it came from.

What does the source label in the last column mean?

It names the strongest source behind that dose. An FDA label is strongest, followed by a published human trial. “No human dose shown to work” means no controlled trial has found one. See how every source label works.

Each page shows the source behind its schedule. When one drug has two product labels, their schedules stay separate.

A GLP-1 tablet with no injection behind it

3 rules for a missed dose, quoted rather than tightened into advice.

Peptide and bacteriostatic-water calculator for any vial

Concentration, units per dose and doses per vial, with the arithmetic printed.

Every tablet strength on one label

6 rules about how and when it is swallowed, taken off the label rather than summarized.

What the Victoza label sets as a starting dose

The Victoza label names 1.2 mg and 1.8 mg as doses to settle on.

How MOTS-c differs from the rest of its class

No published human dosing schedule was found for MOTS-c.

The Trulicity steps, week by week

3 approved uses on the Trulicity label, each dated to the FDA letter that granted it.

What returns besides the weight

Weight is not the only thing measured after stopping; waist and blood pressure were recorded too.

The Zepbound ladder as its own label prints it

Read from the Eli Lilly and Company label for Zepbound, revision 02/2026.

45primary sources, each with the day we read it — open the documents used on this page